Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.40 |
| ▸ | TPMT | P51580 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1198757 | 0.81 | GSK3B (0.61) | GSK3BPTPN1TPMTRAB9AHCAR1 | |
| SCHEMBL1194011 | 0.81 | GSK3B (0.46) | GSK3BPTPN1WDR5 | |
| SCHEMBL15123216 | 0.78 | TPMT (0.61) | TPMTWDR5HCAR1ALDH1A1MAPT | |
| SCHEMBL1190303 | 0.77 | GSK3B (0.53) | GSK3BPTPN1 | |
| SCHEMBL1852011 | 0.77 | GSK3B (0.52) | GSK3BPTPN1TPMTRAB9AMEN1 | |
| SCHEMBL1195322 | 0.77 | TPMT (0.39) | TPMTRAB9AWDR5HCAR1MEN1 | |
| SCHEMBL766063 | 0.76 | GSK3B (0.56) | GSK3BPTPN1MEN1KMT2A | |
| SCHEMBL1194172 | 0.76 | GSK3B (0.37) | GSK3BPTPN1MEN1KMT2AALDH1A1 | |
| SCHEMBL1169209 | 0.76 | WDR5 (0.39) | GSK3BPTPN1WDR5ALDH1A1 | |
| SCHEMBL5050069 | 0.74 | GSK3B (0.53) | GSK3BPTPN1TPMTRAB9AHCAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466169-B2 | SF5 derivatives as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2013-06-18 | — | — | US | disclosed |
| US-8466169-B2 | SF5 derivatives as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2013-06-18 | — | — | US | disclosed |
| US-8466169-B2 | SF5 derivatives as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2013-06-18 | — | — | US | disclosed |
| EP-2242740-B1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI SA (FR) | 2012-12-12 | — | — | EP | disclosed |
| US-20110034461-A1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20110034461-A1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20110034461-A1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| WO-2009097972-A1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034461-A1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL1, F2RL3 | GSK3B 2612/4885PTPN1 1291/4885TPMT 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.